The APRIL paradox in normal versus malignant B cell biology

por van Attekum, M H A, Kater, A P, Eldering, E
Publicado 2016

P1170: INCIDENCE, TREATMENT AND OUTCOME OF PATIENTS WITH RICHTER’S SYNDROME: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS

por Huisman, F., Al-sarayfi, D., Bellido, M., Mous, R., Vermaat, J. S., Kater, A. P., Nijland, M., Brink, M.
Publicado 2022

Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia

por van Attekum, M H A, Terpstra, S, Slinger, E, von Lindern, M, Moerland, P D, Jongejan, A, Kater, A P, Eldering, E
Publicado 2017

PB1886: LONG-TERM TRENDS IN THE LOSS OF LIFE EXPECTANCY AFTER A DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2018

por Van Der Straten, L., Maas, C. C., Levin, M.-D., Visser, O., Posthuma, E. F., Doorduin, J. K., Langerak, A. W., Kater, A. P., Dinmohamed, A. G.
Publicado 2022

Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1

por Oostvogels, R, Minnema, M C, van Elk, M, Spaapen, R M, te Raa, G D, Giovannone, B, Buijs, A, van Baarle, D, Kater, A P, Griffioen, M, Spierings, E, Lokhorst, H M, Mutis, T
Publicado 2013

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation

por Malcikova, J., Tausch, E., Rossi, D., Sutton, L. A., Soussi, T., Zenz, T., Kater, A. P., Niemann, C. U., Gonzalez, D., Davi, F., Gonzalez Diaz, M., Moreno, C., Gaidano, G., Stamatopoulos, K., Rosenquist, R., Stilgenbauer, S., Ghia, P., Pospisilova, S.
Publicado 2018

P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERATIVE VARIANTS OF MANTLE CELL LYMPHOMA TREATED WITH ACALABRUTINIB

por Le Gouill, S., Długosz-Danecka, M., Rule, S., Luigi Zinzani, P., Goy, A., Smith, S. D., Doorduijn, J. K., Panizo, C., Shah, B., Davies, A., Eek, R., Jacobsen, E., Kater, A. P., Robak, T., Jain, P., Calvo, R., Yang, H., Wang, M.
Publicado 2022

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia

por Hengeveld, P. J., Schilperoord-Vermeulen, J., van der Klift, M. Y., Dubois, J. M. N., Kolijn, P. M., Kavelaars, F. G., Rijken, M., Dobber, J. A., Nasserinejad, K., Kersting, S., Westerweel, P. E., Kater, A. P., Langerak, A. W., Levin, M-D.
Publicado 2023

Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification

por te Raa, G D, Moerland, P D, Leeksma, A C, Derks, I A, Yigittop, H, Laddach, N, Loden-van Straaten, M, Navrkalova, V, Trbusek, M, Luijks, D M, Zenz, T, Skowronska, A, Hoogendoorn, M, Stankovic, T, van Oers, M H, Eldering, E, Kater, A P
Publicado 2015

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research In...

por Rawstron, A C, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, K-A, Liptrot, S, O'Brien, D, de Tute, R M, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, A P, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, J L, Stetler-Stevenson, M, Yuan, C, Broome, H E, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, C M, Emerson, R, Robins, H S, Kirsch, I, Shanafelt, T, Pettitt, A, Kipps, T J, Wierda, W G, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, P
Publicado 2016